{"id":"statins-with-or-without-ezetimibe","safety":{"commonSideEffects":[{"rate":"null","effect":"Muscle pain"},{"rate":"null","effect":"Liver enzyme elevation"},{"rate":"null","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Statins work by reducing the amount of cholesterol produced in the liver, which in turn lowers the amount of low-density lipoprotein (LDL) cholesterol in the blood. Ezetimibe, on the other hand, blocks the absorption of cholesterol in the small intestine, further reducing the amount of cholesterol available to the body.","oneSentence":"Statins inhibit HMG-CoA reductase, a key enzyme in cholesterol biosynthesis, while ezetimibe inhibits the absorption of cholesterol in the small intestine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:34.592Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperlipidemia"},{"name":"Atherosclerotic cardiovascular disease"}]},"trialDetails":[{"nctId":"NCT07474649","phase":"PHASE3","title":"A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events","status":"NOT_YET_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2026-06-01","conditions":"Coronary Atherosclerosis, Mixed Dyslipidemia, Hypercholesterolemia","enrollment":103},{"nctId":"NCT07341958","phase":"NA","title":"INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2)","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2026-02-01","conditions":"Ischemic Stroke or High-risk TIA (ABCD² ≥ 4)","enrollment":242},{"nctId":"NCT07084259","phase":"PHASE4","title":"Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"Hanyang University Seoul Hospital","startDate":"2025-07","conditions":"Coronary Artery Disease","enrollment":352},{"nctId":"NCT06930092","phase":"NA","title":"RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2025-07-01","conditions":"Ischemic Cardiomyopathy","enrollment":158},{"nctId":"NCT06738758","phase":"","title":"Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)","status":"RECRUITING","sponsor":"Yun Dai Chen","startDate":"2024-12-16","conditions":"Acute Coronary Syndromes","enrollment":6000},{"nctId":"NCT04656028","phase":"NA","title":"Genetic Testing and Motivational Counseling for FH","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Center for Therapy and Preventive Medicine","startDate":"2020-06-15","conditions":"Hypercholesterolemia, Familial, Hypercholesterolemia, Familial, 1, Hypercholesterolemia, Familial, 2","enrollment":180},{"nctId":"NCT04968509","phase":"PHASE3","title":"Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis","status":"RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2024-03-22","conditions":"Aortic Stenosis","enrollment":160},{"nctId":"NCT05974345","phase":"","title":"In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-11-03","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":204691},{"nctId":"NCT04895098","phase":"","title":"Statin Monotherapy or Statins in Combination With Ezetimibe in Patients for Prevention of CVD","status":"COMPLETED","sponsor":"Akrikhin","startDate":"2021-06-23","conditions":"Lipid Metabolism Disorders, Cardiovascular Diseases","enrollment":1000},{"nctId":"NCT02715726","phase":"PHASE3","title":"Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-27","conditions":"Hypercholesterolemia","enrollment":615},{"nctId":"NCT01890967","phase":"PHASE2","title":"A Study of LY3015014 in Participants With High Cholesterol","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-06","conditions":"Hypercholesterolemia","enrollment":527},{"nctId":"NCT02984982","phase":"PHASE4","title":"Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-11-15","conditions":"Hypercholesterolemia, Acute Coronary Syndrome","enrollment":206},{"nctId":"NCT01941836","phase":"PHASE2","title":"Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2013-09","conditions":"Hypercholesterolemia","enrollment":349},{"nctId":"NCT02642159","phase":"PHASE4","title":"Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-03-15","conditions":"Dyslipidemia","enrollment":413},{"nctId":"NCT01644188","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-08","conditions":"Hypercholesterolemia","enrollment":720},{"nctId":"NCT01112423","phase":"PHASE2","title":"Safety Study of BMS-823778 in Subjects With Hypercholesterolemia","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-06","conditions":"Dyslipidemia","enrollment":60},{"nctId":"NCT01266876","phase":"PHASE2","title":"Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2011-01","conditions":"Hypercholesterolemia","enrollment":77}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":75926,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Hydroxymethylglutaryl-Coenzyme A Reductase inhibitors","Ezetimibe"],"phase":"phase_3","status":"active","brandName":"Statins with or without ezetimibe","genericName":"Statins with or without ezetimibe","companyName":"Beijing Anzhen Hospital","companyId":"beijing-anzhen-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Statins, with or without ezetimibe, are used to treat conditions such as familial hypercholesterolemia and hypercholesterolemia. Statins work by inhibiting the Niemann-Pick C1-like protein 1 (NPC1-like intracellular cholesterol transporter 1), a mechanism that is targeted by small molecule inhibitors like ezetimibe.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}